Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

@article{Hanna2004RandomizedPI,
  title={Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.},
  author={N. Hanna and F. Shepherd and F. Fossella and J. R. Pereira and F. de Marinis and J. von Pawel and U. Gatzemeier and T. C. Tsao and M. Pless and T. Muller and H. Lim and C. Desch and K. Szondy and R. Gervais and Shaharyar and C. Manegold and S. Paul and P. Paoletti and L. Einhorn and P. Bunn},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 9},
  pages={
          1589-97
        }
}
  • N. Hanna, F. Shepherd, +17 authors P. Bunn
  • Published 2004
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. PATIENTS AND METHODS Eligible patients had a performance status 0 to 2, previous treatment with one prior chemotherapy regimen for advanced NSCLC, and adequate organ function. Patients received pemetrexed 500 mg/m(2) intravenously (i.v.) day 1 with vitamin B(12), folic acid, and dexamethasone or docetaxel 75 mg/m(2) i.v… Expand

Paper Mentions

Interventional Clinical Trial
This is a phase 3 double-blinded randomized multicenter clinical trial of SCT-I10A or placebo plus docetaxel with previously treated squamous cell non-small cell lung cancer patients… Expand
ConditionsSquamous-cell Non-Small-cell Lung Cancer
InterventionDrug
Interventional Clinical Trial
MEK162 has shown significant inhibition of tumor growth as a single agent in NSCLC xenograft models in mice and human cancer cells in vitro, which have KRAS and/or other mutations. These… Expand
ConditionsLungcancer
InterventionDrug
Interventional Clinical Trial
Gefitinib, the first EGFR-tyrosine kinase inhibitor (TKI) in the world was examined as monotherapy in two phase Ⅱ studies called IDEAL trials. Response rate with doses of 250mg and… Expand
ConditionsNon-small Cell Lung Cancer
InterventionDrug
Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
TLDR
The comparable efficacy and superior tolerability of pemetrexed compared with docetaxel in this study supports the use of single-agent, second-line pemetrixed for advanced non-squamous NSCLC in Chinese patients. Expand
Phase II Study of Pemetrexed and Cisplatin, with Chest Radiotherapy Followed by Docetaxel in Patients with Stage III Non-small Cell Lung Cancer
  • S. Gadgeel, J. Ruckdeschel, +9 authors A. Turrisi
  • Medicine
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2011
TLDR
Integrating pemetrexed in a concurrent therapy regimen for patients with stage III NSCLC is feasible and was associated with a median survival of 34 months and overall survival of 66%. Expand
Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy.
TLDR
The combination of carboplatin plus paclitaxel is an active and well-tolerated regimen for the treatment of NSCLC patients who have previously been treated with chemotherapy and have a good PS. Expand
Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer
TLDR
This cisplatin-free regimen with gemcitabine plus pemetrexed had good tolerance and achieved promising overall survival with extended 1- and 2-year survival rates. Expand
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
  • Y. Kim, E. Cho, +11 authors D. B. Shin
  • Medicine
  • Cancer research and treatment : official journal of Korean Cancer Association
  • 2016
TLDR
Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC, however, pemberrexed is considered more effective than gef itinib for EGFR wild-type patients. Expand
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
  • E. Smit, S. Burgers, +8 authors H. Groen
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
PC as second-line treatment for relapsed NSCLC resulted in a significant 33% reduction of the hazard of disease progression as compared with pemetrexed alone, and adenocarcinoma was associated with favorable outcome. Expand
Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
  • D. Spigel, J. Hainsworth, +6 authors F. Greco
  • Medicine
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2010
TLDR
Biweekly administration of pemetrexed and gemcitabine seems to be well tolerated with activity comparable with other first-line NSCLC regimens, and whether biweekly scheduling could be an effective strategy to shorten overall treatment duration will require a randomized design. Expand
Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.
TLDR
Treatment with pemetrexed resulted in equivalent efficacy outcomes and better safety profiles compared with docetaxel in second-line therapy for advanced NSCLC in Chinese lung cancer population. Expand
A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer
  • R. Heist, P. Fidias, +4 authors T. Lynch
  • Medicine
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2008
TLDR
Treatment with oxaliplatin and pemetrexed in combination with the targeted antiangiogenic agent bevacizumab yielded promising efficacy with manageable toxicity in the previously treated advanced NSCLC population. Expand
A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.
TLDR
Oral topotecan appears to be active and well tolerated when administered as a fixed dose daily for 5 of every 7 days for 2 weeks every 21 days and might provide another treatment alternative for patients with advanced-stage NSCLC. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 17 REFERENCES
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
TLDR
Patients who received docetaxel had a longer time to progression and a greater progression-free survival at 26 weeks and the 1-year survival was significantly greater with D75 than with the control treat... Expand
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
TLDR
Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m(2), the benefits of docetAXel therapy outweigh the risks. Expand
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
TLDR
Treatment with pemetrexed plus cisplatin and vitamin supplementation resulted in superior survival time, time to progression, and response rates compared with treatment with cis Platin alone in patients with malignant pleural mesothelioma. Expand
Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
TLDR
MTA seems to have clinically meaningful activity as a single agent against advanced NSCLC, and nonhematologic toxicity was generally mild or moderate, but 39% of patients developed a grade 3 skin rash. Expand
ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study.
TLDR
ALIMTA is active in a second-line setting in non-platinum-pretreated NSCLC patients progressing within 3 months of first-line chemotherapy, and this study demonstrates that it is possible to evaluate new drugs against non-small-cell lung cancer in aSecond Line setting. Expand
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
  • R. Grilli, A. Oxman, J. Julian
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
TLDR
Chemotherapy is effective in the treatment of advanced NSCLC, but its impact on the length of survival is limited, and future RCTs should still include an untreated control group and should measure quality of life in addition to survival. Expand
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
TLDR
The results of this meta-analysis suggest that chemotherapy may have a role in treating non-small cell lung cancer, and reached conventional levels of significance when used with radical radiotherapy and with supportive care. Expand
Current Data with Pemetrexed in Non-Small-Cell Lung Cancer
TLDR
Pemetrexed (Alimta®) is a novel multitargeted antifolate that inhibits 3 enzymes involved in folate metabolism and purine and pyrimidine synthesis that has broad antitumor activity in phase II trials in a wide variety of solid tumors. Expand
Current data with pemetrexed (Alimta) in non-small-cell lung cancer.
  • A. Adjei
  • Medicine
  • Clinical lung cancer
  • 2003
TLDR
Pemetrexed (Alimta) is a novel multitargeted antifolate that inhibits 3 enzymes involved in folate metabolism and purine and pyrimidine synthesis that has broad antitumor activity in phase II trials in a wide variety of solid tumors. Expand
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
TLDR
The Southwest Oncology Group has extended the toxicity criteria, incorporating additional new criteria for biological agents, radiation therapy, surgery, and hormonal agents. Expand
...
1
2
...